Reactive Thrombocytosis in Non-aneurysmal Subarachnoid Hemorrhage

Abstract

Background The role of reactive thrombocytosis in non-aneurysmal subarachnoid hemorrhage (NA-SAH) is largely unexplored to date. Therefore, the impact of a quantitative thrombocyte dynamic in patients with NA-SAH and its clinical relevance were analyzed in the present study.

Methods In this retrospective analysis, 113 patients with nontraumatic and NA-SAH treated between 2003 and 2015 at our institution were included. World Federation of Neurosurgical Societies admission status, cerebral vasospasm, delayed infarction, hydrocephalus, need for ventriculoperitoneal (VP) shunt, and Fisher grade were analyzed for their association with reactive thrombocytosis.

Results Reactive thrombocytosis was not associated with hydrocephalus (p ≥ 0.05), need for VP shunt implantation (p ≥ 0.05), cerebral vasospasm (p ≥ 0.05), or delayed cerebral ischemia (p ≥ 0.05).

Conclusion Our study is the first to investigate the role of thrombocyte dynamics, reactive thrombocytosis, and the clinical course of NA-SAH patients. Our analysis showed no significant impact of thrombocyte count on NA-SAH sequelae.

Keywords

non-aneurysmal subarachnoid hemorrhage - stroke and blood coagulation - hemostasis - platelets

Publikationsverlauf

Eingereicht: 31. März 2019

Angenommen: 30. Juli 2019

Artikel online veröffentlicht:
21. Mai 2020

• Reference

• 1 Vora AJ, Lilleyman JS. Secondary thrombocytosis. Arch Dis Child 1993; 68 (01) 88-90
• 2 Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84 (02) 613-617
• 3 Pizzulli L, Yang A, Martin JF, Lüderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998; 19 (01) 80-84
• 4 Nanavati A, Patel N, Burke J. Thrombocytosis and coronary occlusion. JACC Cardiovasc Interv 2012; 5 (06) e18-e19
• 5 Buss DH, Cashell AW, O'Connor ML, Richards II F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96 (03) 247-253
• 6 Schafer AI. Thrombocytosis. JAMA 2015; 314 (11) 1171-1172
• 7 Alberio L. Do we need antiplatelet therapy in thrombocytosis? Pro. Diagnostic and pathophysiologic considerations for a treatment choice. Hamostaseologie 2016; 36 (04) 227-240
• 8 Hirashima Y, Hamada H, Kurimoto M, Origasa H, Endo S. Decrease in platelet count as an independent risk factor for symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 2005; 102 (05) 882-887
• 9 Ansar S, Larsen C, Maddahi A, Edvinsson L. Subarachnoid hemorrhage induces enhanced expression of thromboxane A2 receptors in rat cerebral arteries. Brain Res 2010; 1316: 163-172
• 10 Yokota M, Tani E, Fukumori T, Maeda Y, Yamaura I. Effects of subarachnoid hemorrhage and a thromboxane A2 synthetase inhibitor on intracranial prostaglandins. Surg Neurol 1991; 35 (05) 345-349
• 11 Perez P, Lukaszewicz A-C, Lenck S, Nizard R, Drouet L, Payen D. Platelet activation and aggregation after aneurysmal subarachnoid hemorrhage. BMC Neurol 2018; 18 (01) 57
• 12 Mehta BP, Sims JR, Baccin CE, Leslie-Mazwi TM, Ogilvy CS, Nogueira RG. Predictors and outcomes of suspected heparin-induced thrombocytopenia in subarachnoid hemorrhage patients. Intervent Neurol 2014; 2 (04) 160-168
• 13 Benken ST, Tesoro EP, Kim KS, Mucksavage JJ. Treatment outcomes of heparin-induced thrombocytopenia in subarachnoid hemorrhage patients: a 4-year, retrospective single-center review. Neurocrit Care 2012; 17 (02) 177-182
• 14 Powner DJ, Hoots WK. Thrombocytosis in the NICU. Neurocrit Care 2008; 8 (03) 471-475
• 15 Dubinski D, Won S-Y, Behmanesh B. , et al. Influence of ABO blood type on the outcome after non-aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) 2018; 160 (04) 761-766
• 16 Ionita CC, Graffagnino C, Alexander MJ, Zaidat OO. The value of CT angiography and transcranial doppler sonography in triaging suspected cerebral vasospasm in SAH prior to endovascular therapy. Neurocrit Care 2008; 9 (01) 8-12
• 17 Nijsten MW, ten Duis HJ, Zijlstra JG. , et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med 2000; 28 (12) 3843-3846
• 18 Gurung AM, Carr B, Smith I. Thrombocytosis in intensive care. Br J Anaesth 2001; 87 (06) 926-928
• 19 Kasius KM, Frijns CJM, Algra A, Rinkel GJE. Association of platelet and leukocyte counts with delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2010; 29 (06) 576-583
• 20 Schebesch K-M, Woertgen C, Brawanski A, Rothoerl RD. A study of possible correlation between subarachnoid haemorrhage related vasospasm and the post-bleed blood platelet count chart in a Caucasian population. Acta Neurochir (Wien) 2007; 149 (04) 387-391
• 21 Bruder M, Won S-Y, Wagner M. , et al. Continuous acetylsalicylic acid treatment does not influence bleeding pattern or outcome of aneurysmal subarachnoid hemorrhage: a matched-pair analysis. World Neurosurg 2018; 113: e122-e128
• 22 van den Bergh WM, Algra A, Dorhout Mees SM. , et al; MASH Study Group. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke 2006; 37 (09) 2326-2330
• 23 Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; (04) CD006184
• 24 Dasenbrock HH, Yan SC, Gross BA. , et al. The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis. J Neurosurg 2017; 126 (02) 537-547